AUTL AUTOLUS THERAPEUTICS PLC US FDA Inspections 8-K Filing 2024 - FDA Accepts BLA for obecabtagene autoleucel Autolus Therapeutics plc announced that the FDA has accepted its Biologics License Application for obecabtagene autoleucel for patients with relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia, with a target action date of November 16, 2024.Get access to all SEC 8-K filings of the AUTOLUS THERAPEUTICS PLC